Adipose tissue as an endocrine organ

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 16, Issue 4, 2002, Pages 639-651

  Prins, Johannes B ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adiponectin; Adipose tissue; Corticosteroids; Hormone; Interleukin; Leptin; Steroids; Tumour necrosis factor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACYLATION STIMULATING PROTEIN; ADIPONECTIN; AGOUTI PROTEIN; COMPLEMENT; CORTICOSTEROID; FATTY ACID; HORMONE; INTERLEUKIN 6; LEPTIN; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; SEX HORMONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; BRAIN; CARDIOVASCULAR FUNCTION; COMPLEMENT ACTIVATION; DRUG EFFECT; DRUG MECHANISM; ENDOCRINE FUNCTION; ENDOCRINE GLAND; ENERGY CONSERVATION; HORMONAL REGULATION; HORMONE ACTION; HORMONE DEFICIENCY; HORMONE METABOLISM; HORMONE RELEASE; HUMAN; IMMUNITY; LIVER; NEUROENDOCRINE SYSTEM; NONHUMAN; NUTRITIONAL STATUS; OBESITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPRODUCTION; REVIEW; SKELETAL MUSCLE; ADIPOCYTE; ADIPOSE TISSUE CELL; CARDIOVASCULAR RISK; GLUCOSE METABOLISM; INSULIN RESISTANCE; LIPID METABOLISM; LYMPHOID CELL; PROTEIN METABOLISM; WEIGHT REDUCTION;

EID: 0036919780     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.2002.0222     Document Type: Review

References (97)

1. Zhang Y, Proenca R, Maffei M et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
2. Ahima RS & Flier J. Adipose tissue as an endocrine organ. Trends in Endocrinology and Metabolism 2000; 11: 327-329.
3. Mohamed-Ali V, Pinkney J & Coppack AW. Adipose tissue as an endocrine and paracrine organ. International Journal of Obesity 1998; 22: 1145-1158.
4. Coleman DL. Effects of parabiosis of obese with diabetes and normal mice. Diabetologia 1973; 9: 294-298.
5. Prins JB & O'Rahilly S. Regulation of adipose cell number in man. Clinical Science 1997; 92: 3-11.
6. Kissebah AH & Krakower GR. Regional adiposity and morbidity. Physiological Reviews 1994; 74: 761-811.
7. Bergman R, Van Citters G, Mittleman S et al. Central role of the adipocyte in the metabolic syndrome. Journal of Investigative Medicine 2001; 49: 119-126.
8. Sewter C, Digby J, Blows F et al. Regulation of tumour necrosis factor-alpha release from human adipose tissue in vitro. Journal of Endocrinology 1999; 163: 33-38.
9. Ledgerwood EC & Prins JB. TNF alpha. In Marshall SM, Home PD & Rizza R (eds) Diabetes Annual 12, 1st edn. Oxford: Elsevier, 1998.
10. Hotamisligil GS & Spiegelman BM. Tumor necrosis factor alpha: A key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
11. Hotamisligil GS, Shargill NS & Spiegelman BM. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
12. Jequier E. A metabolic perspective on the interaction between obesity and diabetes. Current Opinion in Endocrinology and Diabetes 1996; 3: 10-15.
13. Hotamisligil GS, Peraldi P & Spiegelman BM. The molecular link between obesity and diabetes. Current Opinion in Endocrinology and Diabetes 1996; 3: 16-23.
14. Hotamisligil GS, Arner P, Caro JF et al. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. Journal of Clinical Investigation 1995; 95: 2409-2415.
15. Kern P, Ranganathan S, Li C et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. American Journal of Physiology, Endocrinology and Metabolism 2001; 280: E745-E751.
16. Kern PA, Saghizadeh M, Ong JM et al. The expression of tumor necrosis factor in human adipose tissue. Journal of Clinical Investigation 1995; 95: 2111-2119.
17. Katsuki A, Sumida Y, Murashima S et al. Serum levels of tumor necrosis factor-α are increased in obese patients with noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 1998; 83: 859-862.
18. Dandona P, Weinstock R, Thusu K et al. Tumor necrosis factor-α in sera of obese patients: Fall with weight loss. Journal of Clinical Endocrinology and Metabolism 1998; 83: 2907-2910.
19. Löfgren P, Van Harmelen V, Reynisdottir S et al. Secretion of tumor necrosis factor-α shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue. Diabetes 2000; 49: 688-692.
20. Hube F, Birgel M & Hauner H. Expression pattern of tumour necrosis factor receptors in subcutaneous and omental human adipose tissue: Role of obesity and non-insulin-dependent diabetes mellitus. European Journal of Clinical Investigation 1999; 29: 672-678.
21. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. International Journal of Obesity 2000; 24 (supplement 4): S23-S27.
22. Liu LS, Spelleken M, R''hrig K et al. Tumor necrosis factor α acutely inhibits insulin signaling in human adipocytes. Diabetes 1998; 47: 515-522.
23. Peraldi P, Hotamisligil GS, Buurman WA et al. Tumor necrosis factor (TNF)-α inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. Journal of Biological Chemistry 1996; 271: 13 018-13 022.
24. Hube F & Hauner H. The two tumor necrosis factor receptors mediate opposite effects on differentiation and glucose metabolism in human adipocytes in primary culture. Endocrinology 2000; 141: 2582-2588.
25. Stephens JM, Lee J & Pilch PF. Tumor necrosis factor-α-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin-receptor-mediated signal transduction. Journal of Biological Chemistry 1997; 272: 971-976.
26. Kanety H, Feinstein R, Papa MZ et al. Tumor necrosis factor α-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Journal of Biological Chemistry 1995; 270: 23 7780-23 784.
27. Hotamisligil GS, Peraldi P, Budavari A et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 1996; 271: 665-668.
28. Hotamisligil GS, Murray DL, Choy LN et al. Tumor necrosis factor α inhibits signaling from the insulin receptor. Proceedings of the National Academy of Sciences of the USA 1994; 91: 4854-4858.
29. Ranganathan S & Davidson MB. Effect of tumor necrosis factor-α on basal and insulin-stimulated glucose transport in cultured muscle and fat cells. Metabolism 1996; 45: 1089-1094.
30. Uysal KT, Wiesbrock SM, Marino MW et al. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 1997; 389: 610-614.
31. Scheen AJ, Castillo MJ, Paquot N et al. Neutralization of TNFα in obese insulin-resistant human subjects: No effect on insulin sensitivity. Diabetes 1996; 45 (supplement): 286A.
32. Ofei F, Hurel S, Newkirk J et al. Effects of engineered human anti-TNFα antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881-885.
33. Petruschke TH & Hauner H. Tumor necrosis factor-α prevents the differentiation of human adipocyte precursor cells and causes delipidation of newly developed fat cells. Journal of Clinical Endocrinology and Metabolism 1993; 76: 742-747.
34. Prins JB, Niesler CU, Winterford CM et al. Tumor necrosis factor-α induces apoptosis of human adipose cells. Diabetes 1997; 46: 1939-1744.
35. Hauner H, Petruschke T, Russ M et al. Effects of tumour necrosis factor alpha (TNFα) on glucose transport and lipid metabolism of newly-differentiated human fat cells in culture. Diabetologia 1995; 38: 764-771.
36. Van Der Poll T, Romijn JA, Endert E et al. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. American Journal of Physiology 1991; 261: E457-E465.
37. Mohamed-Ali V, Goodrick S, Rawesh A et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. Journal of Clinical Endocrinology and Metabolism 1997; 82: 4196-4200.
38. Jones TH. Interleukin-6: An endocrine cytokine. Clinical Endocrinology 1994; 40: 703-713.
39. Vozarova B, Weyer C, Hanson K et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obesity Research 2001; 9: 414-417.
40. Fried SK, Bunkin DA & Greenberg AS. Omental and subcutaneous adipose tissue depots of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. Journal of Clinical Endocrinology and Metabolism 1998; 83: 847-850.
41. Bastard J-P, Jardel C, Bruckert E et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. Journal of Clinical Endocrinology and Metabolism 2000; 85: 3338-3342.
42. Wallenius V, Wallenius K, Ahrén B et al. Interleukin-6-deficient mice develop mature-onset obesity. Nature Medicine 2002; 8: 75-79.
43. Choy LN, Rosen BS & Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. Journal of Biological Chemistry 1992; 267: 12 736-12 741.
44. Flier JS, Cook KS, Usher P et al. Severely impaired adipsin expression in genetic and acquired obesity. Science 1987; 237: 405-408.
45. Rosen BS, Cook KS, Yaglom J et al. Adipsin and complement factor D activity: An immune-related defect in obesity. Science 1989; 244: 1483-1487.
46. Napolitano A, Lowell BB, Damm D et al. Concentration of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass. International Journal of Obesity 1994; 18: 213-218.
47. Sniderman AD, Maslowska M & Cianflone K. Of mice and men (and women) and the acylation-stimulating protein pathway. Current Opinion in Lipidology 2000; 11: 291-296.
48. Baldo A, Sniderman AD, St.-Luce S et al. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. Journal of Clinical Investigation 1993; 92: 1543-1547.
49. Murray I, Havel P, Sniderman AD et al. Reduced body weight, adipose tissue, and leptin levels despite increased energy intake in female mice lacking acylation-stimulating protein. Endocrinology 2000; 141: 1041-1049.
50. Biesma D, Hannema A, Van Velzen-Blad H et al. A family with complement factor D deficiency. Journal of Clinical Investigation 2001; 108: 233-240.
51. Shimomura I, Funahashi T, Takahashi M et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nature Medicine 1994; 2: 800-803.
52. Morange P-E, Aubert J, Pieretti F et al. Glucocorticoids and insulin promote plasminogen activator inhibitor I production by human adipose tissue. Diabetes 1999; 48: 890-895.
53. Kato K, Satoh H, Endo Y et al. Thiazolidinediones down-regulate plasminogen activator inhibitor type I expression in human vascular endothelial cells: A possible role for PPARγ in endothelial function. Biochemical and Biophysical Research Communications 1999; 258: 431-435.
54. Marx N, Bourcier T, Sukhova G et al. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression. Thrombosis and Vascular Biology 1999; 19: 546-551.
55. Karlsson C, Lindell K, Ottosson M et al. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. Journal of Clinical Endocrinology and Metabolism 1998; 83: 3925-3929.
56. Morris AD & Donnelly R. Angiotensin II: An insulin-sensitizing vasoactive hormone? Journal of Clinical Endocrinology and Metabolism 1996; 81: 1303-1306.
57. Jones BH, Standridge MK & Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997; 138: 1512-1519.
58. Frederich RC, Kahn B, Peach M et al. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992; 19: 339-344.
59. Abel ED, Peroni O, Kim J et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001; 409: 729-733.
60. Kraegan E & Cooney GJ. The role of free fatty acids in muscle insulin resistance. In Marshall S, Home P & Rizza R (eds) The Diabetes Annual/12 pp 141-160. Amsterdam: Elservier, 1999.
61. Van Epps-Fung M, Williford J, Wells A et al. Fatty acid-induced insulin resistance in adipocytes. Endocrinology 1997; 138: 4338-4345.
62. Storlein LH, Kriketos AD, Calvert GD et al. Fatty acids, triglycerides and syndromes of insulin resistance. Prostaglandins, Leukotrienes and Essential Fatty Acids 1997; 57: 379-385.
63. Boden G & Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. Journal of Clinical Investigation 1995; 96: 1261-1268.
64. Bollheimer LC, Skelly RH, Chester MW et al. Chronic exposure to free fatty acid reduces pancreatic β cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase in proinsulin biosynthesis translation. Journal of Clinical Investigation 1998; 101: 1094-1101.
65. Dobbins RL, Chester MW, Stevenson BE et al. A fatty acid-dependent step is critically important for both glucose- and non-glucose stimulated insulin secretion. Journal of Clinical Investigation 1998; 101: 2370-2376.
66. Rebrin K, Steil GM, Getty L et al. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 1995; 44: 1038-1045.
67. Oakes ND, Cooney GJ, Camilleri S et al. Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding. Diabetes 1997; 46: 1768-1774.
68. Hansen PA, Han DH, Marshall BA et al. A high fat diet impairs insulin stimulation of glucose transport in muscle. Journal of Biological Chemistry 1998; 273: 26 157-26 163.
69. Dresner A, Laurent D, Marcucci M et al. Effects of free fatty acids of glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. Journal of Clinical Investigation 1999; 103: 253-259.
70. Kliewer SA, Sundseth SS, Jones SA et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proceedings of the National Academy of Sciences of the USA 1997; 94: 4318-4323.
71. Forman BM, Chen J & Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and γ. Proceedings of the National Academy of Sciences of the USA 1997; 94: 4312-4317.
72. Desvergne B & Wahli W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocrine Reviews 1999; 20: 649-688.
73. Kahn B & Flier J. Obesity and insulin resistance. Journal of Clinical Investigation 2000; 103: 473-481.
74. Oakes ND, Thalén P, Jacinto S et al. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 2001; 50: 1158-1165.
75. Miyazaki Y, Glass L, Triplitt C et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001; 44: 2210-2219.
76. Pan DA, Lillioja S, Milner MR et al. Skeletal muscle membrane lipid composition is related to adiposity and insulin action. Journal of Clinical Investigation 1995; 96: 2802-2808.
77. Hu E, Liang P & Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. Journal of Biological Chemistry 1996; 271: 10697-10703.
78. Arita Y, Kihara O, Ouchi N et al. Paradoxical decrease on an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications 1999; 257: 79-83.
79. Combs T, Berg A, Obici S et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. Journal of Clinical Investigation 2001; 108: 1875-1881.
80. Berg A, Combs T & Scherer P. ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism. Trends in Endocrinology and Metabolism 2002; 13: 84-89.
81. Berg A, Combs T, Du X et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Medicine 2001; 7: 947-953.
82. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 2001; 7: 941-946.
83. Maeda N, Takahashi M, Funahashi T et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099.
84. Steppan C, Balley S, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
85. Way J, Görgün C, Tong Q et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor γ agonists. Journal of Biological Chemistry 2001; 276: 25651-25653.
86. Smith U. Resistin - Resistant to defining its role. Obesity Research 2002; 10: 61-62.
87. Savage D, Sewter CP, Klenk E et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-γ action in humans. Diabetes 2001; 50: 2199-2202.
88. Janke J, Engeli S, Gorzelniak K et al. Resistin gene expression in human adipocytes is not related to insulin resistance. Obesity Research 2002; 10: 1-5.
89. Flier JS & Maratos-Flier E. Obesity and the hypothalamus: Novel peptides for new pathways. Cell 1998; 92: 437-440.
90. Ollmann MM, Wilson BD, Yang Y-K et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997; 278: 135-138.
91. Klebig ML, Wilkinson JE, Geisler JG et al. Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proceedings of the National Academy of Sciences of the USA 1995; 92: 4728-4732.
92. Voisey J, Imbeault P, Hutley L et al. BMI-related human adipocyte agouti expression is sex-specific but not anatomically depot-specific. Obesity Research 2002 (in press).
93. Montague CT, Farooqi IS, Whitehead JP et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903-908.
94. Farooqi I, Jebb SA, Langmack G et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. New England Journal of Medicine 1999; 341: 879-884.
95. Oral E, Simha V, Ruiz E et al. Leptin-replacement therapy for lipodystrophy. New England Journal of Medicine 2002; 346: 570-572.
96. Stewart P, Boulton A, Kumar S et al. Cortisol metabolism in human obesity: Impaired cortisone to cortisol conversion in subjects with central adiposity. Journal of Clinical Endocrinology and Metabolism 1999; 84: 1022-1027.
97. Bujalska I, Kumar S & Stewart PM. Does central obesity reflect 'Cushing's disease of the omentum'? Lancet 1997; 349: 1210-1213.